Quantified expression differences of U/FAS pathway genes (Figure 1b) in HR vs. LR NB patients were consistent with these hazard ratios, revealing significant upregulation of all U/FAS genes except ACACA, ELOVL5, and ELOVL2 in HR disease (Figure 4a), which is consistent with the HR patient gene enrichment clusters and Cox regression analysis (Figure 2b and Figure 3a). This evidence concerns the gene ELOVL2 and neuroblastoma.